TuHURA Files IND for TBS-2025 in AML and Blood Cancers
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
HOUSTON, Texas, June 8, 2026 Coya Therapeutics, Inc. announced a significant milestone in the ongoing ALSTARS clinical trial, with...
REDWOOD CITY, California, April 30, 2026 Corcept Therapeutics Incorporated announced compelling two-year overall survival data from its Phase 2...
LEXINGTON, Mass., April 3, 2026 Agenus Inc. has announced that new data from its Phase II clinical study evaluating...
December 16, 2025 – Cambridge, Massachusetts — Atom Therapeutics has announced the initiation of a multi-regional Phase 2 clinical...
Encinitas, California — December 1, 2025 — Kiora Pharmaceuticals has been granted a new U.S. patent (US-12,472,263) covering additional...
LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root...
SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...
